RICHARD HALL: Open Payments
NPI 1134871643 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,767 in 197 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $342 · 2025 $3,767
Food & beverage: $3,658Education: $109
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 22 | $629 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $588 |
| E.R. Squibb & Sons, L.L.C. | 25 | $452 |
| Vanda Pharmaceuticals Inc. | 15 | $414 |
| Teva Pharmaceuticals USA, Inc. | 23 | $376 |
| Alkermes, Inc. | 19 | $360 |
| Otsuka America Pharmaceutical, Inc. | 14 | $234 |
| ABBVIE INC. | 24 | $219 |
| Lundbeck LLC | 10 | $202 |
| Axsome Therapeutics, Inc. | 7 | $162 |
Products named: INGREZZA, CAPLYTA, COBENFY, FANAPT, ARISTADA, VRAYLAR, AUSTEDO XR, ABILIFY MAINTENA.
Industry payments across AL — which companies pay providers there.
